Given the new therapies—including chaperone therapy with migalastat and ERT—available for FD, why do you believe there should be a “call to action” among the CV community that would heighten awareness of this disease?

Given the new therapies—including chaperone therapy with migalastat and ERT—available for FD, why do you believe there should be a “call to action” among the CV community that would heighten awareness of this disease?

CLICK HERE FOR CME CREDIT

Given the new therapies—including chaperone therapy with migalastat and ERT—available for FD, why do you believe there should be a “call to action” among the CV community that would heighten awareness of this disease?

Created by

CMEducation Resources IQ&A Fabry Disease Diagnostic Intelligence Zone

Presenter

John Jefferies, MD

John Jefferies, MD

Jay M. Sullivan Endowed Chair in Cardiovascular Medicine
Chief of Cardiology
University of Tennessee Health Science Center (UTHSC)
Co-Director, UT Methodist Institute for Cardiovascular Science
University of Tennessee Heart Institute
Memphis, TN